Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks

M. S. Turner, D. B. May, R. R. Arthur, Glen Xiong

Research output: Contribution to journalArticlepeer-review

49 Scopus citations


The selective serotonin reuptake inhibitors (SSRIs) are extensively used for the treatment of multiple psychiatric conditions. In vitro and ex vivo data with these agents indicate they may have varying degrees of antiplatelet activity via multiple receptors. Reports of bleeding in patients receiving SSRIs appeared soon after their introduction. A review of the literature suggests SSRI therapy may increase the risk of bleeding especially with concomitant aspirin or nonsteroidal anti-inflammatory agents. Clinicians should exercise caution when prescribing these agents in high risk patients and maintain awareness of the potential contribution of SSRIs to unexplained bleeding episodes.

Original languageEnglish (US)
Pages (from-to)205-213
Number of pages9
JournalJournal of Internal Medicine
Issue number3
StatePublished - Mar 2007
Externally publishedYes


  • Adverse drug reaction
  • Bleeding
  • Coagulopathy
  • Platelet
  • Selective serotonin reuptake inhibitor

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Clinical impact of selective serotonin reuptake inhibitors therapy with bleeding risks'. Together they form a unique fingerprint.

Cite this